Bevarest

Bevarest is a brand name of Bevacizumab, categorized as monoclonal anti-body & anti-angiogenesis Bevarest is a combined human monoclonal antibody IgG1, that predicament to and prohibits the biological activity of human vascular endothelial growth factor (VEGF)

Bevacizumab

Bevarest

100mg/4ml

Emcure




Bevarest indication



Metastatic colon or rectal cancer

In combination with 5-fluorouracil chemotherapy administered intravenously, first or second line drug of choice

Non-squamous, non-small cell lung cancer

Concurrent use with carboplatin and paclitaxel as first line therapy

Glioblastoma

Used in the treatment of recurrent Glioblastoma in adults

Metastatic renal cell cancer

Concurrent use with interferon alfa

Metastatic cervical cancer

Concurrent use with paclitaxel & cisplatin or paclitaxel & topotecan

Epithelial ovarian, fallopian tube or peritoneal cancer

In concomitant use with paclitaxel, pegylated liposomal doxorubicin or topotecan



Mechanism of action


Bevarest comprises an active compound like Bevacizumab which binds to VEGF and avoid the communication of VEGF to its receptors like Flt-1 & KDR) present on the surface of the cells This interaction prevents endothelial cell multiplication and new blood vessel production occurs Thus in counts discontinuation of metastatic tumor cells growth happens

Pharmacokinetics

The pharmacokinetic form of Bevarest is assayed by measuring total serum Bevacizumab concentration.


The volume of distribution is 2.9 (22%) L

The terminal half life period of Bevacizumab is 20days (11 to 50days)


Blueberrypharma.com-img1

bevarest-100mg
Brand Bevarest
Ingredients Bevacizumab
Strength 100mg/4ml
Manufactured Emcure
Rating

Key point

Bevarest do not administered before at least 28 days following surgery and the wound is completely cured

Metastatic colorectal carcinoma

The prescribed dosage of Bevarest by concomitant with 5-fluorouracil based chemotherapy 5mg/kg of Bevarest for every 2 weeks IV in concomitant with bolus IFL 10mg/kg of Bevarest for every 2 weeks IV in combination with FOLFOX4 5mg/kg IV Bevarest for every 2 weeks or 7.5 mg/kg Bevarest as IV every 3 weeks by concurrently used with fluoropyrimidine Irinotecan or fluoropyrimidine oxaliplatin based therapy

Non-small cell lung cancer

The recommended dosage of Bevarest is 15mg/kg IV for every 3 weeks by combining with carboplatin and paclitaxel

Glioblastoma

10mg/kg of Bevarest administered IV for every 2 weeks

Metastatic renal cell cancer

The prescribed dosage of Bevarest is 10mg/kg IV for every 2 weeks by concurrent use with interferon alfa

Metastatic cervical cancer

The prescribed dosage of Bevarest ; 15mg/kg of Bevarest given intravenously for every 3 weeks by combining with paclitaxel and cisplatin or with paclitaxel and topotecan

Epithelial ovarian, fallopian tube or peritoneal cancer

Platinum opposing
The recommended dosage of Bevarest ; 10mg/kg of Bevarest for every 2 weeks by concurrent use with paclitaxel, pegylated liposomal doxorubicin or topotecan Or The recommended dosage of Bevarest ; 15mg/kg of Bevarest given through IV for every 3 weeks by combining with topotecan

Platinum responsive
The recommended dosage of Bevarest ; 15mg/kg given IV for 3 weeks in concomitant with carboplatin and paclitaxel for 6 to 8 cycles The recommended dosage of Bevarest ; 15mg/kg of Bevarest given IV for 3 weeks by combining with gemcitabine & carboplatin for 6 to 10 cycles

Preparation & administration

Bevarest is intravenous solution At initial infusion: given IV infusion over 90 minutes Following infusions: give second infusion over 60 minutes, if tolerated Administer all following infusion over 30minutes Bevarest IV infusion is prepared in aseptic condition Bevarest 400mg containing 16ml solution whereas 100mg containing 4ml Bevarest dilute into 100ml of 0.9% NS Do not dilute with dextrose solution Discard the remaining portion which is left in a vial

Side Effects

Gastrointestinal perforation and fistulae, Surgery and wound healing complication, Hemorrhage, Arterial thromboembolic events, Venous thromboembolic events, Hypertension, Posterior reversible encephalopathy syndrome, Renal injury & Proteinuria, Infusion reactions, Ovarian failure, Congestive heart failure, Neutropenia, mucosal inflammation, infection, neuropathy, Epistaxis, erythrodysaesthesia

Caution with use in the conditions like

While using Bevarest these are some complications occurred during therapy, care should be taken Hypertension, Posterior reversible encephalopathy syndrome, Gastrointestinal perforations, Wound healing complications, Hemorrhage, Arterial thromboembolic events, Venous thromboembolic events, Embryo fetal toxicity occurs

DRUG INTERACTION OF Xtandi CAPSULE

  • While administering Bevarest with paclitaxel & carboplatin, causes decrease in exposure of paclitaxel after four cycles of therapy
  • While getting patients with paclitaxel & carboplatin leads to increase the paclitaxel exposure at day 6

Contraindication

No contraindication occurred




Pregnancy category: D Bevarest should not be used in pregnancy condition

Breast feeding is also not recommended

Bevarest vial should be stored at 2 to 8°C (36 to 46°F) Single use vial

If patient fail to take the dose or missed the cycle means must consult with oncologist and follow the regular dosing schedule Do not take overdose

Blueberrypharma.com-img2


Quick Contact




Prescription upload






PRESCRIPTION


Blueberrypharma.com , a fully licensed and regulated pharmacy medicine, takes all precautions to strictly abide by the laws and regulations set forth in the dispensing of prescription medications. By placing the order for your prescription medicines, you acknowledge and accept the following terms regarding the purchase of any prescription medicines.

Blueberrypharma.com will not dispense any prescription medication without a valid prescription from a licensed physician.

If you are ordering prescription medication(s), you hereby confirm that you will send us a scanned copy of your valid prescription(s) via email, fax, Whatsapp, or by post, and this prescription shall then be subject to the scrutiny of and approval by our qualified Pharmacists.

The drug information provided in the Blueberrypharma.com is for informative purposes only and this Website is not intended to provide diagnosis, treatment or medical advice. We are not liable for any adverse effects or harm to you as a result of your reliance on the information in the Website.

Blueberrypharma.com requires either the User or Customer or the Caregiver to confirm he/she is completely aware of the indications, side effects, drug interactions, effects of missed dose or overdose of the medicines he/she orders from us. It is imperative to seek professional advice from your physician before purchasing or consuming any medicine from Blueberrypharma.com

At Blueberrypharma.com , a Caregiver can order prescription medicines on your behalf.